Please use this identifier to cite or link to this item: https://observatorio.fm.usp.br/handle/OPI/37052
Full metadata record
DC FieldValueLanguage
dc.contributorSistema FMUSP-HC: Faculdade de Medicina da Universidade de São Paulo (FMUSP) e Hospital das Clínicas da FMUSP
dc.contributor.authorSOUZA, Aline de
dc.contributor.authorYUKUYAMA, Megumi Nishitani
dc.contributor.authorBARBOSA, Eduardo Jose
dc.contributor.authorMONTEIRO, Lis Marie
dc.contributor.authorFALOPPA, Ana Cristina Breithaupt
dc.contributor.authorCALIXTO, Leandro Augusto
dc.contributor.authorARAUJO, Gabriel Lima de Barros
dc.contributor.authorFOTAKI, Nikoletta
dc.contributor.authorLOBENBERG, Raimar
dc.contributor.authorBOU-CHACRA, Nadia Araci
dc.date.accessioned2020-08-20T13:26:15Z-
dc.date.available2020-08-20T13:26:15Z-
dc.date.issued2020
dc.identifier.citationCOLLOIDS AND SURFACES B-BIOINTERFACES, v.193, article ID 111097, 8p, 2020
dc.identifier.issn0927-7765
dc.identifier.urihttps://observatorio.fm.usp.br/handle/OPI/37052-
dc.description.abstractHydroxymethilnitrofurazone (NFOH) is a nitrofurazone derivative and has potential use in treating leishmaniasis. However, due to low water solubility and bioavailability, NFOH has failed in in vivo tests. Nanostructured lipid carrier (NLC) is an alternative to overcome these limitations by improving pharmacokinetics and modifying drug delivery. This work is focused on developing a novel NFOH-loaded NLC (NLC-NFOH) using a D-optimal mixture statistical design and high-pressure homogenization, for oral administration to treat leishmaniasis. The optimized NLC-NFOH consisted of Mygliol (R) 840, Gelucire (R) 50/13, and Precirol (R) ATO 5 as lipids. These lipids were selected using a rapid methodology Technobis Crystal 16 T M, microscopy, and DSC. Different tools for selecting lipids provided relevant scientific knowledge for the development of the NLC. NLC-NFOH presented a z-average of 198.6 +/- 5.4 nm, PDI of 0.11 +/- 0.01, and zeta potential of -13.7 +/- 0.7 mV. A preliminary in vivo assay was performed by oral administration of NLC-NFOH (2.8 mg/kg) in one healthy male Wistar rat (341 g) by gavage. Blood from the carotid vein was collected, and the sample was analyzed by HPLC. The plasma concentration of NFOH after 5 h of oral administration was 0.22 mu g/mL. This same concentration was previously found using free NFOH in the DMSO solution (200 mg/kg), which is an almost 100-fold higher dose. This study allowed a design space development approach of the first NLC-NFOH with the potential to treat leishmaniasis orally.eng
dc.description.sponsorshipFundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP) [2017/08332-3]
dc.language.isoeng
dc.publisherELSEVIEReng
dc.relation.ispartofColloids and Surfaces B-Biointerfaces
dc.rightsrestrictedAccesseng
dc.subjectLeishmaniasiseng
dc.subjectNanoparticle(s)eng
dc.subjectDrug delivery system(s)eng
dc.subjectLipid-based formulation(s)eng
dc.subjectNanostructured lipid carriereng
dc.subjectHydroxymethylnitrofurazoneeng
dc.subject.otherimproved oral deliveryeng
dc.subject.otherdrug-deliveryeng
dc.subject.otherin-vitroeng
dc.subject.otherskin permeationeng
dc.subject.othergelucire 50/13eng
dc.subject.othernanoparticleseng
dc.subject.othersystemeng
dc.subject.othernlceng
dc.subject.otherformulationseng
dc.subject.othercurcumineng
dc.titleA new medium-throughput screening design approach for the development of hydroxymethylnitrofurazone (NFOH) nanostructured lipid carrier for treating leishmaniasiseng
dc.typearticleeng
dc.rights.holderCopyright ELSEVIEReng
dc.identifier.doi10.1016/j.colsurfb.2020.111097
dc.identifier.pmid32417467
dc.subject.wosBiophysicseng
dc.subject.wosChemistry, Physicaleng
dc.subject.wosMaterials Science, Biomaterialseng
dc.type.categoryoriginal articleeng
dc.type.versionpublishedVersioneng
hcfmusp.author.externalSOUZA, Aline de:Univ Sao Paulo, Fac Pharmaceut Sci, Sao Paulo, SP, Brazil
hcfmusp.author.externalYUKUYAMA, Megumi Nishitani:Univ Sao Paulo, Fac Pharmaceut Sci, Sao Paulo, SP, Brazil
hcfmusp.author.externalBARBOSA, Eduardo Jose:Univ Sao Paulo, Fac Pharmaceut Sci, Sao Paulo, SP, Brazil
hcfmusp.author.externalMONTEIRO, Lis Marie:Univ Sao Paulo, Fac Pharmaceut Sci, Sao Paulo, SP, Brazil
hcfmusp.author.externalCALIXTO, Leandro Augusto:Univ Fed Sao Paulo, Inst Environm Chem & Pharmaceut Sci, Dept Exact & Earth Sci, Diadema, SP, Brazil
hcfmusp.author.externalARAUJO, Gabriel Lima de Barros:Univ Sao Paulo, Fac Pharmaceut Sci, Sao Paulo, SP, Brazil
hcfmusp.author.externalFOTAKI, Nikoletta:Univ Bath, Dept Pharm & Pharmacol, Bath, Avon, England
hcfmusp.author.externalLOBENBERG, Raimar:Univ Alberta, Fac Pharm & Pharmaceut Sci, Edmonton, AB, Canada
hcfmusp.author.externalBOU-CHACRA, Nadia Araci:Univ Sao Paulo, Fac Pharmaceut Sci, Sao Paulo, SP, Brazil
hcfmusp.description.articlenumber111097
hcfmusp.description.volume193
hcfmusp.origemWOS
hcfmusp.origem.idWOS:000546723100027
hcfmusp.origem.id2-s2.0-85084472294
hcfmusp.publisher.cityAMSTERDAMeng
hcfmusp.publisher.countryNETHERLANDSeng
hcfmusp.relation.referenceAgrawal Y, 2010, INT J PHARMACEUT, V401, P93, DOI 10.1016/j.ijpharm.2010.09.007eng
hcfmusp.relation.referenceBalguri SP, 2016, EUR J PHARM BIOPHARM, V109, P224, DOI 10.1016/j.ejpb.2016.10.015eng
hcfmusp.relation.referenceBeloqui A, 2016, NANOMED-NANOTECHNOL, V12, P143, DOI 10.1016/j.nano.2015.09.004eng
hcfmusp.relation.referenceChung MC, 2003, BIOORGAN MED CHEM, V11, P4779, DOI 10.1016/j.bmc.2003.07.004eng
hcfmusp.relation.referenceCole ET, 2008, ADV DRUG DELIVER REV, V60, P747, DOI 10.1016/j.addr.2007.09.009eng
hcfmusp.relation.referenceDate AA, 2011, NANOTECHNOLOGY, V22, DOI 10.1088/0957-4484/22/27/275102eng
hcfmusp.relation.referencede Souza A, 2018, INT J PHARMACEUT, V547, P421, DOI 10.1016/j.ijpharm.2018.06.018eng
hcfmusp.relation.referenceEl-Badry M., 2009, Saudi Pharmaceutical Journal, V17, P219eng
hcfmusp.relation.referenceEloy JD, 2012, AAPS PHARMSCITECH, V13, P1436, DOI 10.1208/s12249-012-9868-2eng
hcfmusp.relation.referenceFathi HA, 2018, COLLOID SURFACE B, V162, P236, DOI 10.1016/j.colsurfb.2017.11.064eng
hcfmusp.relation.referenceFreitas C, 1999, EUR J PHARM BIOPHARM, V47, P125, DOI 10.1016/S0939-6411(98)00074-5eng
hcfmusp.relation.referenceGarg NK, 2016, INT J PHARMACEUT, V499, P301, DOI 10.1016/j.ijpharm.2015.12.061eng
hcfmusp.relation.referenceHazzah HA, 2015, J PHARM SCI-US, V104, P3913, DOI 10.1002/jps.24590eng
hcfmusp.relation.referenceHelgason T, 2008, J AM OIL CHEM SOC, V85, P501, DOI 10.1007/s11746-008-1219-9eng
hcfmusp.relation.referenceJain K, 2015, DRUG DELIV, V22, P940, DOI 10.3109/10717544.2014.885999eng
hcfmusp.relation.referenceJannin V, 2006, INT J PHARM, V309, P6, DOI 10.1016/j.ijpharm.2005.10.042eng
hcfmusp.relation.referenceJawahar N, 2018, INT J BIOL MACROMOL, V110, P269, DOI 10.1016/j.ijbiomac.2018.01.121eng
hcfmusp.relation.referenceJeon HS, 2013, INT J PHARMACEUT, V452, P311, DOI 10.1016/j.ijpharm.2013.05.023eng
hcfmusp.relation.referencede los Santos CJJ, 2017, J DRUG DELIV SCI TEC, V42, P261, DOI 10.1016/j.jddst.2017.03.030eng
hcfmusp.relation.referenceJin HH, 2016, J DAIRY SCI, V99, P1780, DOI 10.3168/jds.2015-10391eng
hcfmusp.relation.referenceKar N, 2017, EUR J PHARM SCI, V104, P196, DOI 10.1016/j.ejps.2017.03.046eng
hcfmusp.relation.referenceKasongo KW, 2011, J PHARM SCI-US, V100, P5185, DOI 10.1002/jps.22711eng
hcfmusp.relation.referenceKimura E, 1997, GEN PHARMACOL, V28, P695, DOI 10.1016/S0306-3623(96)00362-Xeng
hcfmusp.relation.referenceKollipara S, 2014, ACTA PHARM SIN B, V4, P333, DOI 10.1016/j.apsb.2014.09.001eng
hcfmusp.relation.referenceLi W, 2015, INT J PHARMACEUT, V495, P948, DOI 10.1016/j.ijpharm.2015.10.011eng
hcfmusp.relation.referenceLi X, 2016, PHARMAZIE, V71, P327, DOI 10.1691/ph.2016.5190eng
hcfmusp.relation.referenceLiu LS, 2017, CURR ORG CHEM, V21, P34, DOI 10.2174/1385272820666160511121400eng
hcfmusp.relation.referenceMAHJOUR M, 1993, INT J PHARM, V95, P161, DOI 10.1016/0378-5173(93)90403-3eng
hcfmusp.relation.referenceMarquele-Oliveira F, 2016, J PHARMACEUT BIOMED, V123, P195, DOI 10.1016/j.jpba.2016.01.045eng
hcfmusp.relation.referenceMonteiro LM, 2019, J GLOB ANTIMICROB RE, V18, P279, DOI 10.1016/j.jgar.2019.06.006eng
hcfmusp.relation.referenceMonteiro LM, 2017, INT J ANTIMICROB AG, V50, P88, DOI 10.1016/j.ijantimicag.2017.01.033eng
hcfmusp.relation.referenceMonteiro LM, 2017, BIOMED RES INT, V2017, DOI 10.1155/2017/9781603eng
hcfmusp.relation.referenceMonteiro LM, 2015, BRAZ J PHARM SCI, V51, P561, DOI 10.1590/S1984-82502015000300008eng
hcfmusp.relation.referenceMuller RH, 2011, EUR J PHARM BIOPHARM, V78, P1, DOI 10.1016/j.ejpb.2011.01.007eng
hcfmusp.relation.referenceNaseri N, 2015, ADV PHARM BULL, V5, P305, DOI 10.15171/apb.2015.043eng
hcfmusp.relation.referenceNegi LM, 2014, INT J PHARMACEUT, V461, P403, DOI 10.1016/j.ijpharm.2013.12.006eng
hcfmusp.relation.referencePatil-Gadhe A, 2016, INT J PHARMACEUT, V501, P199, DOI 10.1016/j.ijpharm.2016.01.080eng
hcfmusp.relation.referenceSerafim EOP, 2013, ANTIMICROB AGENTS CH, V57, P6106, DOI 10.1128/AAC.02522-12eng
hcfmusp.relation.referencePoonia N, 2016, FUTUR SCI OA, V2, DOI 10.4155/fsoa-2016-0030eng
hcfmusp.relation.referenceRamalingam P, 2016, COLLOID SURFACE B, V139, P52, DOI 10.1016/j.colsurfb.2015.11.050eng
hcfmusp.relation.referenceSakloetsakun D, 2013, INT J BIOL MACROMOL, V61, P363, DOI 10.1016/j.ijbiomac.2013.08.002eng
hcfmusp.relation.referenceSalunkhe SS, 2016, DRUG DELIV, V23, P1306, DOI 10.3109/10717544.2014.943337eng
hcfmusp.relation.referenceSeverino P, 2012, J DRUG DELIV, DOI 10.1155/2012/750891eng
hcfmusp.relation.referenceShen J, 2010, NANOTECHNOLOGY, V21, DOI 10.1088/0957-4484/21/2/025101eng
hcfmusp.relation.referenceShen J, 2009, J CONTROL RELEASE, V137, P217, DOI 10.1016/j.jconrel.2009.04.021eng
hcfmusp.relation.referenceSouto EB, 2007, J BIOMED NANOTECHNOL, V3, P317, DOI 10.1166/jbn.2007.049eng
hcfmusp.relation.referenceSouto EB, 2005, J MICROENCAPSUL, V22, P501, DOI 10.1080/02652040500162436eng
hcfmusp.relation.referenceSouto EB, 2004, INT J PHARMACEUT, V278, P71, DOI 10.1016/j.ijpharm.2004.02.032eng
hcfmusp.relation.referenceSznitowska M, 2017, EUR J PHARM BIOPHARM, V110, P24, DOI 10.1016/j.ejpb.2016.10.023eng
hcfmusp.relation.referenceTamjidi F, 2013, INNOV FOOD SCI EMERG, V19, P29, DOI 10.1016/j.ifset.2013.03.002eng
hcfmusp.relation.referenceTan JSL, 2020, J BIOMAT SCI-POLYM E, V31, P141, DOI 10.1080/09205063.2019.1680926eng
hcfmusp.relation.referenceValicherla GR, 2016, SCI REP-UK, V6, DOI 10.1038/srep26895eng
hcfmusp.relation.referenceWang YJ, 2011, DRUG DEV IND PHARM, V37, P1225, DOI 10.3109/03639045.2011.565774eng
hcfmusp.relation.referenceWorld Health Organization, 2010, CONTR LEISHM REP M Weng
hcfmusp.relation.referenceWorld Health Organization, 2015, INT REP COMM END CHI, P1eng
hcfmusp.relation.referenceYukuyama MN, 2019, J DRUG DELIV SCI TEC, V49, P622, DOI 10.1016/j.jddst.2018.12.029eng
hcfmusp.relation.referenceZhang Y, 2013, DRUG DEVELOP RES, V74, P322, DOI 10.1002/ddr.21082eng
hcfmusp.relation.referenceZhang Y, 2013, AAPS J, V15, P523, DOI 10.1208/s12248-013-9459-5eng
hcfmusp.relation.referenceZhao XJ, 2015, INT J NANOMED, V10, P257, DOI 10.2147/IJN.S73322eng
hcfmusp.relation.referenceZhou XT, 2015, INT J PHARMACEUT, V479, P391, DOI 10.1016/j.ijpharm.2014.12.068eng
hcfmusp.relation.referenceZulfiqar B, 2017, ONCOTARGETS THER, V10, P463, DOI 10.2147/OTT.S119362eng
dc.description.indexMEDLINEeng
dc.identifier.eissn1873-4367
hcfmusp.citation.scopus2-
hcfmusp.scopus.lastupdate2022-06-03-
Appears in Collections:

Artigos e Materiais de Revistas Científicas - FM/Outros
Outros departamentos - FM/Outros

Artigos e Materiais de Revistas Científicas - LIM/11
LIM/11 - Laboratório de Cirurgia Cardiovascular e Fisiopatologia da Circulação


Files in This Item:
File Description SizeFormat 
art_SOUZA_A_new_mediumthroughput_screening_design_approach_for_the_2020.PDF.pdf
  Restricted Access
publishedVersion (English)1.05 MBAdobe PDFView/Open Request a copy

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.